UP’s Mega Pharma Park Set to Make State a Powerhouse for Bulk Drug Manufacturing

Unknown Apr 02, 2026 2,750 Views

Uttar Pradesh is gearing up to become India’s next big hub for bulk drug manufacturing with its upcoming state-funded Pharma Park in Lalitpur. This ambitious project, spread across 1,472 acres, is not only expected to rival established pharma giants like Gujarat and Andhra Pradesh but also...

Strategic Vision:

The Lalitpur Pharma Park is a fully state-sponsored initiative designed to make UP self-reliant in bulk drug and Active Pharmaceutical Ingredient (API) manufacturing. With a projected investment of over ₹12,000 crore, the park is set to create nearly 14,000 direct and indirect jobs and attract top industry players.

Modern Infrastructure:

The park offers plug-and-play industrial plots, a centralized R&D and testing facility, common warehousing, a Common Effluent Treatment Plant (CETP), and advanced waste management with Zero Liquid Discharge (ZLD) systems. Support facilities include wide roads, 24/7 power, stormwater drainage, and a dedicated Centre of Excellence for skill development.

Investor Interest:

Already, 26 companies—including Bharat Biotech and Dr Reddy’s Laboratories—have shown interest, with five allotted land and starting unit setup. The state’s investor-friendly policies, transparent online land allotment, and attractive incentives (like discounts for upfront payment and long-term leases) are drawing more pharma giants.

Connectivity & Expansion:

Lalitpur’s location near India’s geographic center, strong road and rail links, and proximity to airports and ports make it an ideal industrial site. The park is scalable up to 5,000 acres if demand rises.

Policy Support:

Under the UP Pharma and Medical Devices Policy 2023, companies benefit from capital and interest subsidies, stamp duty exemptions, electricity duty waivers, and support for patents and clinical trials.

With environmental clearances secured and the first phase already underway, UP’s Pharma Park is poised to transform the state into a national leader in bulk drug manufacturing, boost local employment, and strengthen India’s pharmaceutical self-reliance.

Source: Business Standard, Economic Times Government, Indian Express

Stay Ahead – Explore Now! Nifty 50 Index Trims Gains as Market Sentiment Remains Positive